Our website uses necessary cookies to enable basic functions and optional cookies to help us to enhance your user experience. Learn more about our cookie policy by clicking "Learn More".
Accept All Only Necessary Cookies
Icona AcRIS

1.1.0 by Digital Artefacts L.L.C.


Nov 27, 2021

Informazioni su AcRIS

Sorveglianza delle malattie respiratorie acute (AcRIS)

You are being asked to take part in a study that is sponsored by Pfizer (the “Sponsor”). The Sponsor is providing funding to Ochsner Clinic Foundation to conduct the study. This study is being done completely remotely by using an experimental mobile application downloaded onto your mobile device. This means that you will not have to visit a study site if you choose to take part in this study.

Pfizer is working to better understand if there are voice features that correlate to acute respiratory illness symptoms in particular severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza (flu), and Respiratory Syncytial Virus (RSV). This knowledge may benefit vaccine and therapy development across these and other key disease areas. The data will further characterize self-reported voice and symptom profiles for acute respiratory illness; this may benefit vaccine development across several key disease areas, including influenza and respiratory syncytial virus (RSV) infection.

Novità nell'ultima versione 1.1.0

Last updated on Nov 27, 2021

AcRIS Phase 2 study start!

Traduzione in caricamento...

Informazioni APP aggiuntive

Ultima versione

Richiedi aggiornamento AcRIS 1.1.0

Caricata da

امير الشرعبي

È necessario Android

Android 7.0+

Mostra Altro

AcRIS Screenshot

Commento Loading...
Iscriviti ad APKPure
Sii il primo ad accedere alla versione anticipata, alle notizie e alle guide dei migliori giochi e app Android.
No grazie
Iscrizione
Abbonato con successo!
Ora sei iscritto ad APKPure.
Iscriviti ad APKPure
Sii il primo ad accedere alla versione anticipata, alle notizie e alle guide dei migliori giochi e app Android.
No grazie
Iscrizione
Successo!
Ora sei iscritto alla nostra newsletter.